A carregar...
The molecular mechanisms of acquired proteasome inhibitor resistance
The development of proteasome inhibitors (PIs) has transformed the treatment of multiple myeloma and mantle cell lymphoma. To date, two PIs have been FDA approved, the boronate peptide bortezomib and, most recently, the epoxyketone peptide carfilzomib. However, intrinsic and acquired resistance to P...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3521846/ https://ncbi.nlm.nih.gov/pubmed/22978849 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm300434z |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|